Cargando…

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma

BACKGROUND: Anti-programmed death (PD)-1 therapy has recently been used in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). The long-term survival and its biomarkers responding to anti-PD-1 treatment in patients with R/M NPC remain unclear. METHODS: Patients with R/M NPC were enrolled b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuxiang, Chen, Xi, Wang, Ao, Zhao, Hongyun, Lin, Qingguang, Bao, Hua, Zhang, Yang, Hong, Shaodong, Tang, Wanxiangfu, Huang, Yan, Yang, Yunpeng, Wu, Xue, Shao, Yang, Fang, Wenfeng, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978327/ https://www.ncbi.nlm.nih.gov/pubmed/33737344 http://dx.doi.org/10.1136/jitc-2020-002014

Ejemplares similares

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response
por: LaSalle, Thomas, et al.
Publicado: (2020)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
por: Song, Yuxuan, et al.
Publicado: (2023)

Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
por: Filipski, Katharina, et al.
Publicado: (2021)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma
por: Zeng, Liang, et al.
Publicado: (2023)

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
por: Lv, Kunpeng, et al.
Publicado: (2023)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bhrmlggm8dk0bj16d1k7ckamoe